Recombinant Human IFNA4 | Z102405

abm | Recombinant Human IFNA4 | Z102405

All known subtypes of IFN- alpha show the same antiviral antiparasitic, antiproliferative activities. IFN-alpha forms are produced by monocytes/macrophages, lymphoblastoid cells, fibroblasts, and a number of different cell types following induction by viruses, nucleic acids, glucocorticoid hormones, and low-molecular weight substances. All IFN-alpha subtypes possess a common conserved sequence region between amino acid positions 115-151 while the amino-terminal ends are variable. Many IFN-alpha subtypes differ in their sequences at only one or two positions. IFN-alpha and IFN-beta are thought to bind to the same receptor. Signal transduction mechanisms elicited after binding of IFN-alpha to its receptors involves tyrosine phosphorylation (see also: PTK; protein tyrosine kinase) of various non-receptor tyrosine kinases belonging to the Janus kinases.

Functions:

The ED(50) was determined by the dose-dependent proliferation of KMS15 cells and was found to be <0.05ng/mL.

Organism:

Human

Source:

E. coli

Alias:

Interferon alpha-4B, Interferon alpha-76, Interferon alpha-M1

Gene Symbol:

IFNA4

Gene ID:

3441

Accession:

N/A

Formulation:

N/A

Solubility:

N/A

Appearance:

Lyophilized Powder

Molecular Weight (kDa):

19,6

Molecular Weight 2 (kDA):

N/A

Molecular Weight 3 (kDA):

N/A

Purity:

>95% as determined by SDS-PAGE

Concentration:

<1.0 EU/μg of recombinant protein as determined by the LAL method

Shipping Condition :

Ambient Temperature

Storage Condition:

The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.